Abstract The aim of cost-utility analysis is to support decision making in healthcare by providing a standardised mechanism for comparing resource use and health outcomes across programmes of work. The focus of this paper is the denominator of the cost-utility analysis, specifically the methodology and statistical challenges associated with calculating QALYs from patient-level data collected as part of a trial. We provide a brief description of the most common questionnaire used to calculate patient level utility scores, the EQ-5D, followed by a discussion of other ways to calculate patient level utility scores alongside a trial including other generic measures of health-related quality of life and condition-and population-specific questionnaires. Detail is provided on how to calculate the mean QALYs per patient, including discounting, adjusting for baseline differences in utility scores and a discussion of the implications of different methods for handling missing data. The methods are demonstrated using data from a trial. As the methods chosen can systematically change the results of the analysis, it is important that standardised methods such as patient-level analysis are adhered to as best as possible. Regardless, researchers need to ensure that they are sufficiently transparent about the methods they use so as to provide the best possible information to aid in healthcare decision making.
Introduction
The aim of cost-utility analysis is to aid in decision analysis in healthcare. In particular, it provides a standardised mechanism for comparing resource use and health outcomes across healthcare technologies and disease areas. The term was coined to differentiate it from cost-effectiveness analysis: a health economic evaluation where the denominator of the incremental cost-effectiveness ratio (ICER) is a cost per unit change in a disease-or programme-specific outcome, for instance cost per depressionfree day or cost per infection prevented. Instead, the outcome in the denominator of the cost-utility analysis ICER is a compound measure of mortality and morbidity quantified using preferences or risk in a standardised way [1] . The quantity and quality of life (QOL) is then combined to calculate QALYs, disability-adjusted life-years (DALYs) or a variant thereof. As the units of analysis are standardised, they theoretically make it easier to compare the health and social care resource implications of different programmes and disease areas. It should also be noted that cost-utility analysis is still called cost-effectiveness analysis in the US and in the UK a cost-utility analysis may be referred to as a cost-effectiveness analysis or cost-utility analysis depending on the author's preference [1] .
QALYs are the most commonly used outcome in the denominator of the cost-utility analysis in health technology assessments in developed countries. QALYs are calculated by weighting each year of life lived using a utility score. Utility scores are anchored so that 1 is perfect health and 0 is equivalent to the state of death. In some models negative scores are possible, representing states that are theoretically worse than death. Multiplying time in a health state by the health state utility value, 1 year of life lived in perfect health is equal to 1 QALY. If a person were to live for 2 years in a health state that is weighted as 0.5 of full health, this is also equivalent to 1 QALY. The utility value and, hence, QALYs are valued independently of a person's age, so 1 QALY is the same for someone who is 18 years of age as for someone who is 80 years of age [2] .
The term 'utility' in cost-utility analysis and its theory is based on von Neumann-Morgenstern (vN-M) utility theory. The normative model for utility theory, the model for how a rational individual ought to behave, is that utility scores represent the strength of an individual's preference when faced with uncertainty for a given outcome, in this case a health state. There are a number of conditions that utility scores should meet, and although the model is normative, it should somewhat reflect the way individuals make decisions when faced with uncertainty (some empirical research, however, suggests these conditions may be more often violated than met [2] ). vN-M utility theory also assumes that utility scores are cardinal in that individuals are able to quantify the extent to which they prefer one health state to another. This is as opposed to scores being purely ordinal; individuals are only able to order health states in terms of preference. Theoretically, utility scores that form the basis of QALYs are meant to have these qualities, making them as close as possible to the utility scores in vN-M utility theory [1] . The area, however, is not without its controversies and the terminology used can be confusing. 'Utility' in vN-M utility theory and in the calculation of QALYs should not be confused with the way that the word utility is used in other areas of economics such as welfare theory and Pareto optimisation [2] .
Although the original purpose of cost-utility analysis was to aid in decision making related to the allocation of scarce healthcare resources, the utility scores used to calculate QALYs have found their way into more general analyses of health and social care programmes, with statisticians and economists alike using them to draw conclusions about the effectiveness of health and social care interventions, policies and technologies. Nevertheless, there are a range of methods that analysts can use to calculate QALYs and account for missing data. A literature review by Richardson and Manca [3] identified a number of different ways way that QALYs were calculated in costutility analyses alongside randomised control trials (RCTs). They identified that the calculation of QALYs in many cases lacked consistency and that there was poor reporting of methods. Reporting of missing data and how it was handled were of particular concern, with almost a half of the papers not reporting the amount of missing data and only one-fifth with missing data including and describing a method of data imputation. The authors recommend that cost-utility analyses need to be fully transparent with consistent analytical techniques employed, as different methods can influence the direction and significance of the results [3] . As utility scores gain increasing appeal with a wider range of analytical disciplines, the risk of miscommunication and misinterpretation of analyses of utility scores increases.
The focus of this article is the denominator of the costutility analysis, specifically the calculation of QALYs in the incremental cost per QALY gained analysis. We aim to re-orientate utility scores towards their original standardised purpose and provide guidance to analysts including statisticians, epidemiologists and junior health economists new to economic evaluation on how to calculate QALYs from utility scores collected as part of a trial, highlighting specific statistical issues that are important to address. We firstly provide a brief description of the most common questionnaire used to calculate patient-level utility scores, the EQ-5D, followed by a discussion of other ways to calculate patient-level utility scores alongside a trial including other generic measures of health-related QOL (HR-QOL) and condition-and population-specific questionnaires. In Sect. 5 we go into detail on how to calculate the mean QALYs per patient using patient data that has been collected as part of a trial. Building on the formulas set out in Sect. 5, we describe the methods for discounting and adjusting for baseline differences. In the final two sections we describe different ways to handle missing data, including multiple imputation (MI) in Sect. 8.
Utilities from the EQ-5D
Calculating patient-level utility scores as part of a trial is usually made up of two steps: (1) asking patients to complete a generic measure of HR-QOL at different timepoints over the duration of the trial, including baseline, to measure a patient's health status; and (2) applying a preferencebased algorithm to calculate utility scores for each patient's health status at each timepoint.
The key body responsible for providing advice and guidance on best clinical practice including value for money in England [the National Institute for Health and Care Excellence (NICE)] recommends that utility scores are obtained from a random sample of the general population and that a technique called time trade-off (TTO) should be used to arrive at a measure of preference under uncertainty for a given health state [4] . The generic questionnaire most favoured in the UK is the EuroQol group's EQ-5D and the variant currently most commonly used is the 3-level version. This questionnaire consists of five questions asking if patients have no, some or extreme problems with mobility, self-care, usual activities, pain and anxiety/depression [5] . In total, the questionnaire defines 243 distinct health states, each of which have an associated, country-specific utility score representing the preferences of a sample of the general population of that country. In the UK, the utility scores for the EQ-5D 3-level version ranges from 1 for perfect health to -0.594 (states worse than death are possible with this value set, and are given negative scores) [6] . A 5-level version of the EQ-5D is available and preference-based health state valuations from a random sample of the general population are in the process of being derived [7] .
It should be noted that the issues discussed in this paper are not specific to utility scores derived from the EQ-5D but also relate to other generic measures of HR-QOL and condition-and population-specific measures that have preference-based algorithms and can be used to calculate utility scores for health states. The other methods are discussed in Sects. 3 and 4. If the method used is something other than using a country-specific version of the EQ-5D to calculate QALYs, caution should be exercised when comparing the results of this analysis with others as the results will systematically vary from method to method [8] .
Calculating Utility Scores Using Other Generic Measures
In some instances the view is taken that the EQ-5D is not suitable for a particular patient group or disease [9] . It is also the case that in some trials EQ-5D data are not collected. Data from other generic measures of HR-QOL might have been collected however. Brazier et al. [10] developed a 6-dimension classification of another measure of generic HR-QOL that is commonly used in trials: the SF-36 and SF-12. The 6-dimension classification system, commonly referred to as the SF-6D, then has utility values from members of the general public using the standard gamble (SG) and an algorithm to convert either the SF-36 or SF-12 into a single utility score. Another example includes the multiattribute health status classification system, the Health Utilities Index (HUI), which has associated utility scores derived from a Canadian population [11] . The HUI2, which is designed to be used in children, has a UK algorithm for calculating utility scores [12] . Another generic HR-QOL questionnaire for use in children with an associated UK preference set is the Child Health Utility 9D (CHU 9D) [13] .
Calculating Utility Scores Using Condition-Specific Measures and Mapping
In addition, criticism has been levelled at some of the measures as they do not capture domains of interest; for example, there are no questions in the EQ-5D directly relating to vision, fatigue or cognition [9] . To attempt to address this issue new utility preference sets based on TTO or SG have been generated from a condition-specific questionnaire. This includes in cancer, where a specific utility value set has been generated for the commonly used European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire-Core 30 (EORTC-QLQ-C30) [14] , and in epilepsy where a utility value set has been developed for the NEWQOL-6D questionnaire for epilepsy [15] . Questionnaires and utility value sets have also been generated for specific populations that might struggle to fill in the traditional questionnaires or where extra domains were considered suitable. For example, to address the challenges of QOL measurement for patients with dementia the DEMQoL [16] and its associated value sets [17] have been developed. It is recommended that these questionnaires are used alongside the EQ-5D for consistency, but it is currently unclear what impact that might have on utility estimates [17] . Another issue, particularly pertinent to patients where cognitive ability is limited or they are too unwell to complete the questionnaire, is completion of questionnaires by proxies compared with self-completion. The EQ-5D has a proxy-completed version, although the validation of this has been limited and the viewpoint of the proxy is an important determinant of how the questionnaire is completed and the resulting utility scores [18] . Researchers concerned about consistency are advised to use both proxy and patient completion where possible [17] . This is not always possible, however, and in these instances the person completing the questionnaire should be noted (individual or proxy) and a sensitivity analysis conducted. Another solution for calculating utility scores when EQ-5D data have not been collected is to use a mapping algorithm derived from 'mapping' a generic preferencebased measure of HR-QOL onto a condition-specific questionnaire. Commonly used condition-specific measures with a mapping algorithm are the EORTC-QLQ-C30 in cancer [19] and the Barthel index in stroke care [20] . Extreme caution needs to be exercised when using mapping algorithms, however, as in many cases they can significantly over-or under-predict for some patients, partially because of the methods used to derive the algorithms [21] .
A more thorough discussion of the issues of using a condition-specific instrument for calculating utility scores can be found in Brazier et al. [22] .
Calculating a QALY
The following sections use trial data to illustrate how to calculate QALYs, and the impact that different methods and assumptions can have on the direction and magnitude of the results of an analysis. Following the collection of patient health status as part of the trial, and once the algorithm for that measure is applied to calculate utility scores for patients, the most commonly accepted way to calculate QALYs is to calculate the area under the concentration-time curve (AUC) joining the utility measurements at each point in time [1] . To illustrate the calculation of QALYs, we use trial data from real patients with data on follow-up timepoints of 6 months, 1 year and 2 years for 152 patients (85 in the treatment group and 67 in the control group) [23] 1 . The treatment arm involved a health check at baseline for patients with intellectual disabilities; the control group received usual care. Figure 1 and columns 2 and 3 of Table 1 show mean utility scores calculated from the EQ-5D over the 2-year period for the treatment and control groups and the numbers with complete EQ-5D value sets in Table 2 . The amount of missing data for the EQ-5D at each follow-up point is reported in Table 2 .
There are two broad ways that the AUC can be calculated: (i) at the patient level using patient-level data at each follow-up point; and (ii) at the group level using the mean utility score for each follow-up point.
The recommended method is to calculate QALYs using individuals' utility scores at different timepoints.
The formula to calculate the AUC or QALYs using patient-level data is shown in Eq. 1:
where u is the utility score, i denotes an individual, and t is time so that at baseline t = 0. For each group j (j = 0 for control and j = 1 for treatment), the consecutive time measures are added, averaged and then re-scaled (d) for the percentage of a year that t and t-1 cover, so 0.5 for 6 months or 0.25 for 3 months and so on. For the total duration of the trial, the total QALYs (Q) for each individual are the summation of the QALY calculations for each follow-up timepoint starting at t = 1, the first follow-up point (Eq. 2)
The mean QALYs for each treatment group (Q j ) are then calculated from the individual-level data, dividing the sum of all QALYs for all patients ( P Q ji ) by the number of patients (n) (Eq. 3). Standard deviations, standard errors and confidence intervals can then be calculated using standard formulas from the individual-level data in Eq. 2. Most statistical packages will omit individuals with any missing data on the questionnaire or utility score at any timepoint from the analysis if no adjustment to the analysis is made to account for this. Hence, the resulting analysis will be an individuallevel, complete case analysis (only individuals who have utility scores at baseline and all follow up timepoints will be included). In the example dataset at the final follow-up point, 24 months, 85 % of participants have complete responses to the EQ-5D in the control group and 83 % in the treatment group. Across all timepoints, however, only 70 % of participants in the control group and 71 % of participants in the treatment group have complete responses to the EQ-5D (see Table 2 ). When an individual-level, complete case analysis is run using the example dataset the total mean QALYs for the control group are 1.47 (95 % CI 1.36-1.57) and for the treatment group are 1.39 (95 % CI 1.27-1.51) (see Table 3 ).
When reporting the results of the analysis, the mean utility score and standard deviations for each follow-up point might be reported to provide more detailed information. If this is done then care needs to be taken in reporting and interpreting these results. The mean utility for each treatment group (u jt ), using all individuals with complete data at each timepoint, an available case analysis was calculated using the example dataset and is reported in Table 1 . If these available case means are used to calculate the AUC adjusting for timing (d) (Eq. 4) then summed for the total duration of the trial (Eq. 5), the results differ from the individual-level analysis as additional individuals are included in the analysis. The total QALYs are 1.37 for the control group and 1.35 for the treatment group. A complete breakdown of the mean utility scores at each follow-up point and total mean QALYs as an available case analysis is reported in Table 1 for illustration purposes.
Note that the results are different for the individual-level complete case analysis compared with the available case analysis. If a complete case analysis is conducted using mean follow-up scores at the group level, so only including individuals with complete questionnaires at all points, the results are the same as at the individual level (see Table 3 ). It is important to note that both of these examples are for illustrative purposes only, so as to provide a description of the calculation of QALYs. Neither complete case analysis nor available case analysis adequately addresses the issue of missing data and, hence, both of them are biased. This is discussed further in Sect. 8.
Both of these analyses also assume that the line drawn between utility scores, and hence QALYs, are linear. This significantly simplifies the analysis as the assumption of linearity allows two consecutive utility scores to be averaged and then multiplied by the duration between the two Missing 1 item on EQ-5D 4 (6) 9 (11)
Missing EQ-5D 6 (9) 5 (6) Complete across all timepoints 47 (70) 60 (71) scores. Some authors, however, have experimented with non-linear changes between consecutive timepoints (e.g. Miyamoto [24] ). These models are considerably more complex and, although they will report different results to a linear model, will only make a minimal difference to the results over short trial durations or if follow-up timepoints are close. Authors such as Billingham et al. [25] have also investigated assumptions regarding changes over time and mortality using survival analysis and provided recommendations for calculating QALYs. The SF-36 was also administered to patients in the example trial at baseline and the last follow-up point (2 years). Applying the SF-6D algorithm developed by Brazier et al. [10] and doing a complete case analysis, the mean QALYs for the control group and treatment group are 1.51 (95 % CI 1.45-1.57) and 1.54 (95 % CI 1.48-1.60), respectively.
Note that the final score for the SF-36 and associated SF-6D algorithm is higher than that of the EQ-5D. This is common for studies using the SF-6D, partially because the range of utility scores for the two algorithms are not the same. Whereas the range of possibility utility values for the EQ-5D ranges from 1 to -0.594, with a number of health states that have utility scores worse than death, scores on the SF-6D are anchored at 1 for perfect health but with a minimum score of 0.316. As a result, the SF-6D tends to be worse at discriminating between responses for patients in worse states of health. At the upper ranges, though, it tends to discriminate better, having less of a ceiling effect than the EQ-5D [26] . If using the SF-6D rather than the EQ-5D for an analysis, one must be careful of this systematic bias when interpreting the results of the ICER.
Discounting
In a cost-utility analysis both costs and QALYs need to be adjusted for the different times that they occur. Discounting is the process of accounting for time preferences in the receipt of costs or benefits. The standard discount rate used by NICE for both costs and benefits is 3.5 % [4] , with a standard of 3 % being consistent across other developed countries including the USA [27] . For public health interventions NICE recommends a discount rate for costs and benefits of 1.5 % [28] . Discounting can be done using group means or individual-level data, although it is recommended that discounting is done at the individual level, particularly due to issues associated with missing data, as is discussed in Sect. 8. Equation 6 is the discount formula for calculating QALYs at an individual level using the utility score (u) for individual i at time t for a discount rate of r:
The discount rate is generally only applicable in cases where the duration of the trial is greater than 12 months. In this formula, t is the time from baseline in years. It is possible, however, to perform a monthly discount rate by converting the yearly discount rate r to a monthly value (Eq. 7). The same discount rate formula still applies, but instead using the new 1-month rate and t becomes the time from baseline in months. In the case of a discount rate of 3.5, 0.3 % would be the monthly discount rate using Eq. 7: Discounting has been applied to the example dataset at the group level (available case analysis) to provide a worked example (see Table 1 ). When applied at the individual level (complete case analysis), the new mean QALYs are 1.44 (95 % CI 1.34-1.54) and 1.37 (95 % CI 1.25-1.48).
Adjusting for Baseline Differences
Random allocation to the treatment or control group is the most common mechanism used in trials to try to ensure balanced characteristics between the treatment and control groups. However, randomisation is not a perfect mechanism for this and sometimes differences can occur between groups in patient characteristics that might have a significant impact on the results of the trial. For example, by chance, individuals in the control group may have more severe disease symptoms at baseline than individuals in the treatment group. Hence, other additional methods are sometimes used to try to minimise the impact that differences between groups can have on the results of the analysis, some of which can occur prior to randomisation, such as stratification. Stratification is where patients are randomised to intervention groups in such a way as to try to reduce significant differences between groups for a specific important characteristic, such as co-morbidities or symptom severity. Stratification can also be used in very specific situations, such as controlling for the random allocation to treatment groups between countries in a multi-country trial.
Another common technique, particularly in observational data, is adjusting for baseline characteristics where there is strong reason to believe that they could influence the outcome of interest. Adjusting for baseline differences in groups does come with caveats. Generally, including variables used for stratification as covariates in a regression analysis is considered acceptable, and in some instances baseline variables that are known a priori to be strongly or moderately associated with the dependent variable in the analysis. However, it is important to note that variables that were measured after randomisation or that could be influenced post hoc by the treatment in any way should not be included as covariates for the purposes of baseline adjustment and the variables chosen should also be specified in the analysis plan [29] .
Imbalances in baseline values have a different implication for the analysis in the calculation of QALYs. QOL is not a variable that is included in stratification and is generally a dependent variable, not a covariate in an analysis, so it is not intuitively adjusted for. It is possible, though, that the treatment or control group may differ in QOL or utility scores at baseline. The nature of calculating QALYs as AUC then means that one group may have more QALYs by virtue of their baseline utility scores alone, particularly if the treatment only has a minimal effect on QOL. In the example dataset, by chance, the utility score for the control group is higher than for the treatment group [0.68 (95 % CI 0.61-0.74) versus 0.63 (95 % CI 0.57-0.70), respectively], although not significantly higher.
There are a number of methods that can be used to adjust for baseline utility score differences, with linear regression with baseline adjustment being the recommended method [29] .
One approach that has commonly been used, and is the most intuitive, is to calculate the difference in utility score from baseline, so that only the actual change in utilities is computed and baseline differences are removed. Looking at the group means in Table 1 only, in the control group there is an increase of 0.04 from baseline over the 2 years and for the treatment group an increase of 0.17. Using the individual-level data in the example dataset, the mean difference in utility score from baseline for the control group is -0.02 (95 % CI -0.8 to 0.4) and for the treatment group is 0.16 (95 % CI 0.09-0.23), with the increase in utility score being significantly different in the treatment compared with the control group. However, this methodology presents significant problems for calculating QALYs for hypothesis testing as only the less informative mean difference from baseline is calculated. This method has also been criticised in the literature as it fails to control for imbalances due to regression to the mean; patients' future scores are generally correlated with their past scores [30] .
Instead, the method that has been recommended is linear regression with baseline adjustment. In this instance, QALYs for each individual are calculated as described in Sect. 5. A linear regression analysis is then run where the dependent variable is the total QALYs, b 1 is the coefficient for the treatment effect and b 2 the coefficient for baseline utility scores (Eq. 8):
In this linear regression analysis the coefficient for b 1 is then the difference in QALYs between treatment and control. In a standard statistics package such as STATA Ò this can be done by running the regression analysis (regress total QALYs treatment_dummy_variable baseline_utility). Running this analysis on the example dataset, the treatment co-efficient, b 1 , is 0.029 (95 % CI -0.067 to 1.262). The mean adjusted QALYs for each treatment group can also be calculated using most standard statistical packages. In STATA Ò this is done by using the command adjust after running the regression analysis, and adjusting for baseline utility scores at mean [margins treatment_group, at(baseline_utility = mean)]. If this is done in the example dataset, the mean patient-level QALYs for the control group are 1.35 (95 % CI 1.28-1.43) and for the treatment group they are 1.38 (95 % CI 1.32-1.45) undiscounted. Including discounting they are 1.33 (95 % CI 1.26-1.40) and 1.36 (95 % CI 1.3-1.42) (see Table 3 ). Note that this method only adjusts for baseline utility scores and not other baseline characteristics, which, as mentioned above, is to be done with caution unless they are stratified variables or they are prespecified in the analysis plan.
In this example, although adjusting for baseline differences does not change the conclusion (there is a non-significant difference between treatment and controls even after adjusting for baseline differences) it does change the direction of the difference from negative to positive. Although there is no difference in QOL between the two groups, and thus does not change the conclusion of the analysis, it may have an impact on the results of a costutility analysis once costs are added in. This is discussed further in Sect. 9.
Other statistical methods of varying levels of sophistication, particularly those that are designed to account for a range of baseline patient characteristics, are also possible. An example would be to fit a multi-level model with fixed and random effects. One option, which is explained more fully in Carpenter and Kenward [31] , is to account for the repeated measures of utility within a patient as the response variable and include a random effect accounting for baseline response at the patient level. This approach has the statistical advantage of parameterising the baseline measurement (e.g. accounting for measurement error on that value) and enabling analysis of data that are incomplete (e.g. subjects with only endpoint values may be included). Fitting this multi-level model assuming a fixed effect for the treatment coefficient, the estimated mean undiscounted QALYs for the control group is 1.55 (95 % CI 1.47-1.62) with an estimated reduction of QALYs for the treatment group of -0.0029 (95 % CI -0.11 to 0.11).
Missing Data
Missing data is a well-documented problem in healthcare datasets and methods to address it will almost always need to be considered within the statistical and economic evaluation analysis plan for any repeated-measures patientlevel dataset. In the first instance, however, it can be considered a trial design issue, where by trialists and research staff should ensure that the methods and resources they use to recruit and retain patients try to minimise the risk of missing data as best possible. In terms of costs for economic evaluations this can be addressed by taking data from medical records. However, for questionnaires that are not routine, this presents more of a challenge. Length of the questionnaire has been shown to have a negative correlation with the probability of responding, so shorter and fewer questionnaires are preferable [32] . In this way, the EQ-5D can be a good questionnaire given its relatively short length.
Once the data have been obtained, and the level of missingness ascertained, it is up to the analysts to handle the missing data appropriately. This would include an assessment of the mechanism of missingness. Are the data missing completely at random (MCAR)? This is where there is no relationship between the data that is missing and any values in the dataset, missing or observed. Is the data missing at random (MAR)? This is where the missingness is not related to the missing data but an observed variable in the dataset. Or the missing data can be missing not at random (MNAR) where the propensity for data to be missing is related to the missing data. When data are MAR, observed data can be used to estimate the results. There are different ways to test which observed variable predicts the missing data if data are MAR, which are covered more fully in Little and Rubin [33] , but once the mechanism for missingness is ascertained the most appropriate method for handling missing data needs to be chosen, taking into account the data available. It should be noted, though, that there is no way to test if data are MCAR, given that there is a chance that the propensity for data to be missing is as a result of some individual characteristic that is missing from the dataset.
A recent systematic review of economic evaluations alongside RCTs found that missing data were rarely handled appropriately and in one-fifth of cases it was unclear if it had been accounted for or was not mentioned at all. In one-third of cases complete case analysis was the analysis method chosen [34] . However, complete case analysis is considered a poor statistical technique for dealing with missing data as it significantly biases the results. It makes the assumption that individuals whose data is missing within a dataset have the same characteristics as those with complete data; i.e. that the data is MCAR. In most clinical trials this is unlikely to be the case. The most common bias is that individuals whose disease is more severe or who do not respond as well to treatment are more likely to have missing data, as they may be more unwell or have lost interest in the trial given it has provided them with no benefit. Individuals who fail to comply with treatment are also less likely to show up for further assessments and hence are more likely to have missing data.
The percentage of missing data points in the example dataset at each follow-up timepoint is reported in Table 2 . At 24 months, 57 individuals have complete data in the control group and 71 in the treatment group. This represents approximately 85 % of the participants in both groups. The main analysis used thus far has been a complete case analysis. Only 47 individuals in the control group and 60 in the treatment have complete data over the full duration of the trial, representing 70 % of participants. To determine if there is an observable mechanism by which data are missing, comparisons can be made between fully observed baseline characteristics, such as age, sex and intellectual ability, and the missing outcome (utility scores). One can then define a variable R, where R = 1 if utility scores are observed at all follow-up points for an individual, or R = 0 if there are any missing observations. It is then possible to test for differences in the rate of missingness (R) for fully observed baseline variables using simple statistical tests such as Chisquare for categorical observed variables and t tests for continuous variables. Although no relationship in the example dataset was found between level of learning disability (mild, moderate, severe or profound) and missingness or sex and missingness, age was significantly related to the amount of missing data, with the older the individual the more likely they had missing data. EQ-5D utility scores at baseline were also significantly lower for individuals with missing data. In this instance, one can hypothesise that data are not MAR, but that older individuals with lower QOL are less likely to return subsequent questionnaires.
There are a number of ways that one can work with missing data, although only three are dealt with here: (i) taking the last utility value forward; (ii) taking the last questionnaire value forward; and (iii) MI. These particular methods have been chosen because they illustrate two types of missing data analysis (simple and random) and the impact different methods can have on the outcome of the analysis. Taking the last value forward (examples i and ii) can be considered a simple approach to missing data. Another simple approach to missing data, which is not addressed here, is imputing mean values. This particular option has not been chosen as from the previous analysis above it is clear that individuals with missing values vary systematically from those who do not, specifically having lower baseline utility values. Imputing mean results for follow-up scores would bias the results of the analysis as it would potentially artificially inflate the follow-up utility scores. There are more ways to deal with missing data than the examples given. A more complete review of the literature is available in Eekhout et al. [35] . As a general rule, however, MI is the most appropriate technique to use when analysing patient-level datasets with missing data. A more complete tutorial on MI methods is also available in White et al. [36] .
Last Value Forward: Utility Score
An assumption one might make when calculating the AUC is that the QOL or utility score of patients with missing data at point t is the same utility score they experienced in the previous timepoint (t-1). This essentially draws a straight, horizontal line from the last point with available data to the next point where data is available to calculate the AUC. It does introduce bias, though, in that if the reason individuals were unable to complete questionnaires is because their health deteriorated and they were too unwell to reply, then the values for these individuals will be artificially inflated.
If this assumption is applied to the example dataset, then the mean unadjusted, undiscounted QALYs for each group using a patient-level analysis (Eq. In some instances utility scores cannot be calculated because not all items of the questionnaire are completed, rather than the whole questionnaire being missing; this is sometimes referred to as ''item non-response'' (as opposed to unit non-response, where the whole questionnaire is missing). In the example dataset, one item missing from the questionnaire accounted for a significant proportion of the missing utility scores at 6-and 24-month follow-ups. Similar to the previous method, the last value given for that question in the previous timepoint can be assumed to be the same in this instance and EQ-5D scores can be calculated from there.
If this assumption is applied to the example dataset, then the mean unadjusted, undiscounted QALYs for each group using a patient-level analysis (Eq. 5) are 1.34 (95 % CI 1.23-1.46) for the control group and 1.35 (95 % CI 1.25-1.46) for the treatment group; including discounting and adjusting for baseline values (Eq. 8), the mean QALYs are 1.3 (95 % CI 1.22-1.37) for the control group and 1.35 (95 % CI 1.28-1.42) for the treatment group.
The values are very similar to those where utility is replaced. As a result, one can argue that it does not matter whether you replace a missing utility score or questionnaire values. On the other hand, the main underlying assumption behind this strategy is that given the past history, missingness is completely non-informative. Thus, it is reasonable to assume that patients will continue to show the same behaviour as they have in the past. In most cases, this seems too stringent an assumption, thus potentially limiting the usefulness of these methods. In this instance, given that the patients with the lowest utility are those that are the most likely to have missing values, using either of the last value forward methodologies does nothing to address the systematic bias associated with the missingness of the data. In any case, it should be pointed out that the results are strongly dependent on this assumption and thus extensive sensitivity analysis is recommended.
Multiple Imputation
One method that usually overcomes the severe limitations of last value forward and other simple imputation methods is that of stochastic MI. The basic idea is to 'impute' the values that have not been observed with a summary obtained using the available data. Typically, this is done by taking random draws from a suitable probability distribution to account for the underlying uncertainty in the summary statistic. This random draw is used to represent the potential observation that just happens not to be available. A distinct characteristic of analyses based on MI is that rather than having a singular dataset where missing values are replaced by a new value, as is the case with simple imputation methods, for MI the original dataset remains as is, along with the missing values, and a number of new datasets are created where a new value is inserted in place of the missing one. In each new dataset the new imputed value varies between datasets, within likely ranges for the parameter, and can be based on prespecified relationships with observed baseline characteristics, as is described below. In summary, a number of new hypothetical datasets are created with different values imputed for the missing data, leaving the original dataset intact. The same analyses as previous are then run on the new datasets, which are combined using appropriate methods, to obtain an estimate of the parameter of interest, the standard error and the standard deviation.
The selected probability model describes the joint variation of observed and unobserved values. One simple way of doing so is to set up a regression model (on a suitable scale), in which the variable for which missing data are present depends on some fully observed covariates. A byproduct of this procedure is that it automatically takes into account the patient characteristics that are (a) available to the researcher and (b) considered to be predictive of the missing mechanism. Of course, from the computational point of view, this implies that the analysis is generally more complex and requires more advanced statistical tools.
To choose the number of imputed datasets to create, a general rule of thumb is to create m imputed datasets such that m is equal to the number of percentage points of missing data for the dependent variable [36] . In the example dataset, across all timepoints a utility score was missing for 30 % of datapoints, and hence 30 imputed datasets were created. Previously, when less computing power was available to run analyses it was generally recommended that three to ten datasets were created, with limited extra benefit obtained after ten [33] . Given the additional computing power available today, even generating hundreds of imputed datasets will have little impact on the time taken to run analyses on relatively small trial datasets. However, to test that an adequate number of datasets have been generated, White et al. [36] suggested the following additional tests: They set a third assertion for the p value given that the assumption is that p should be less than 0.05. Given that trials are rarely powered to find a difference in QALYs between treatment and control groups, it is unlikely that there will be a difference between the two groups and, hence, this condition is rarely relevant for QALYs. The Monte-Carlo estimate can be calculated in STATA Ò using the command mcerr following the command mi estimate.
The only observed complete baseline variable available that was informative of missingness in the example dataset, as described above, was age. In STATA Ò , while the data were still in long format (multiple observations for each individual in the one column) it was declared as long (mi set mlong), EQ-5D utility scores were declared as the variable to be imputed (mi register impute utility score variable), and 30 imputed datasets were created using regression analysis and age as an informative observed variable [mi impute regress utility score age, add(30)]. The data were then reshaped into wide, using Rubin's rule to combine information on each individual, using the ''mi reshape'' command in STATA Ò and further analyses carried out using ''mi estimate''. A regression analysis run on the imputed data estimated that the mean undiscounted and unadjusted QALYs for the control group were 1.36 (95 % CI 1.25-1.47), with the treatment group having 0.02 QALYs less on average (95 % CI -0.17 to 0.127). Adjusting for baseline differences in utility scores, the treatment group had a QALY increase of 0.02 (95 % CI -0.089 to 0.129).
Probability Distribution
The examples above do not address the distribution of utility data. Utility scores derived from the EQ-5D have a number of distribution issues in that, in addition to having the qualities of a maximum value of 1 and minimum value of -0.594, EQ-5D utility scores tend to be positively skewed with an identifiable ceiling effect 2 . Figure 2 is the frequency distribution of the EQ-5D utility data at baseline from the example dataset. It is clear from the graph that EQ-5D utility scores in this example are not normally distributed. The most common way of addressing this in cost-utility analysis is to use non-parametric tests of significance, with the recommended method being bootstrapping [27] , where N samples of n individuals are taken from the original dataset and then replaced. The process is then repeated a large number of times (upwards of 1,000), and for each of these samples the mean of the sample is calculated. Further statistics can then be run on these results. Additionally, if these means are then stored in memory, this has the added advantage that alongside bootstrapped cost data, cost-effectiveness planes and costeffectiveness acceptability curves can be created that allow for reporting the percentage of times that the mean of samples for a given option are cost effective for a willingness to pay for a QALY. Other methods that can take into account the distribution of the data and some of the other issues discussed above are more complex regression techniques and seemingly unrelated equations that can also be used for hypothesis testing of cost and utility data but are beyond the scope of this article [37] .
Conclusion
Utility scores and the calculation of QALYs present a number of statistical analysis challenges, some of which are due to the nature of clinical trials, such as missing data. This paper has demonstrated that the methods used are important as they can impact on the direction or magnitude of the results, although in this instance not necessarily the conclusions. Use of standardised methods is recommended so as to maintain the original intended purpose of utilities and QALYs-comparison across disease areas and different programmes of work. If this is not possible, however, analysts need to ensure that they are transparent about their methods and any assumptions made regarding the above areas so that decision makers and others are able to make informed decisions about the effectiveness of a new technology and whether to implement it or to conduct further research.
